CRS Clinical Research Services

From 90 to Just 45 Days - Accelerated Approval Times for Mononational Clinical Trials in Germany! Exciting news for clinical research in Germany! The German Federal Institute for Drugs and Medical Devices (BfArM), the Paul-Ehrlich-Institute (PEI), and the Working Group of Medical Ethics Committees (AKEK) have approved a significantly shortened processing period for mononational clinical trials. What does this mean for your work with CRS? The timeline for study submission to approval for mononational clinical trials in Germany has been cut from approximately 90 days to approximately 45 days. This change positions CRS as your go-to partner for efficient and expedited clinical trials in the EU. With these streamlined processes, CRS can offer clients even more efficient project timelines, enabling quicker study starts and faster time-to-market for new therapies. This accelerated approval process benefits our clients and enhances our ability to bring innovative treatments to patients sooner. Partner with CRS to take advantage of these shortened deadlines and experience unparalleled efficiency in your clinical trial processes. Together, we can drive the future of clinical research and deliver life-changing therapies to those in need. Let's make a difference together, faster. #CRS #Healthcareinnovation #Clinicaltrials #Medicalresearch #Germany #Berlin #Mannheim #Kiel

🚀 Advancing Obesity Treatment Research 🚀 We are pleased to share important advancements in obesity management, guided by the expertise of our Chief Medical Officer Thomas Forst, Prof. Dr., Head of Medical Affairs Dr. Sara Armani, and Clinical Investigator Dr. med. Maria Marinez. Their recent research explores incretin-based therapies, including GLP-1 receptor agonists, which are showing promise in supporting weight loss and overall health improvement! 🌟 Key Insights from the Research: Significant Weight Loss: Patients achieved a 6% to 21% reduction in body weight, with many losing over 10%. Health Benefits: These treatments may help reduce cardiovascular risks, prevent diabetes, aid liver health, and support weight maintenance after surgery. Innovation in Progress: With dual and triple co-agonists under development, we are dedicated to evaluating these emerging therapies. While these treatments offer substantial potential, challenges such as cost, potential weight re-gain, and side effects still need further exploration. Our team remains committed to developing more effective treatments to combat obesity and enhance patient care worldwide. 🙌 🌍 Read the full study here: https://lnkd.in/ehg_a-xB #ObesityResearch #IncretinTherapies #GLP1 #CRS #WeightManagement #HealthInnovation #PatientCare

📅 Mark Your Calendars! 🎉 We are delighted to share that we will once again be participating in the BVMA Symposium in Munich this year! This year's theme, "New Impulses for Clinical Research," will focus on pivotal topics such as "Digitalization in Clinical Research," "Germany as a Hub for Clinical Studies - Let's Tackle It!" and "AI - Applications and Opportunities." This symposium offers us an excellent opportunity to exchange insights, collaborate with industry leaders and explore cutting-edge advancements that are shaping the future of our industry. Check out the Bundesverband Medizinischer Auftragsinstitute e.V. (BVMA) website for more details about the symposium and registration details: https://www.bvma.de/ Join us as we contribute to shaping the future of clinical trials. We look forward to connecting with you! #BVMA2024 #CRS #ClinicalResearch #Digitalization #AI #Germany #Munich

🌟 Spotlight: Dr. Sara Armani at EPHAR 2024! We are delighted to inform you that our Medical Director and Head of Medical Affairs, Dr. Sara Armani, recently attended EPHAR 2024 - 9th European Congress of Pharmacology! This event united pharmacologists from across Europe and the globe, fostering collaboration and the exchange of groundbreaking ideas in the field of pharmacology. While at EPHAR, Dr. Armani also had the privilege of meeting with representatives from the British Pharmacological Society. This fruitful exchange focused on collaborative efforts to advance our shared goals of enhancing drug development and improving patient outcomes around the world. At CRS, we are dedicated to leading scientific advancements and building strong medical partnerships. Stay tuned as we drive innovation and shape the future of clinical research. 💪 💊 #EPHAR2024 #Pharmacology #CRS #ClinicalExcellence #Collaboration

🚀 Exciting News! 🚀 We are delighted to report that we received BfArM approval for a clinical study in just 39 days with only 5 Requests for Information (RFI). This achievement highlights our efficient processes and dedicated team. 💪 🌟 This swift approval underscores the advantage of conducting clinical research in Germany. Join us in celebrating this milestone and discover the benefits of partnering with CRS! #CRS #ClinicalResearch #ClinicalTrials #BfArM #GermanEfficiency 

🌟 Spotlight: Dr. Abir Alatrach on the Cover of Deutsche Dermatologie! We are thrilled to announce that our Dermatology Consultant, Dr Abir Alatrach, has been featured on the cover of Deutsche Dermatologie, a leading academic dermatology magazine by Springer Medizin! 🏆 Congratulations Dr Abir Alatrach! We are incredibly proud to have such a distinguished expert on our team.👏 Read the issue here: https://lnkd.in/ekweqNwP #Dermatology #Kiel #CRS #InnovationInDermatology #PursuitofExcellence

🚨 Job Alert! 🚨 We are excited to announce an opportunity for a Medical Director at our Kiel unit! Are you a medical professional with a good command of English and German with a passion for transforming healthcare? Join our dedicated team in Kiel, Germany, where we collaborate with leading pharmaceutical and biotech companies to conduct research aimed at improving patient outcomes. Want to know more? Click here to apply: https://lnkd.in/eyKaxCmk We are looking forward to hearing form you!

🚀 Exciting Times at the Nutrition Conference 2024 in Leipzig! 🌟 Last week, our CMO and COO Thomas Forst, Prof. Dr. and Investigator Friedeborg Seitz had the privilege of attending the 2024 Nutrition Conference (Kongress Ernährung) in Leipzig. The event, held under the motto "Health is Sustainable," focused on the impact of nutrition on planetary health. It was a fantastic opportunity to explore interdisciplinary and innovative approaches, as well as current research findings in nutrition and therapy across various fields such as pediatrics, neurological diseases, intensive care medicine, obesity, and much more. 📸 Check out some highlights from the event below! We're thrilled to share these moments with you and look forward to implementing the insights gained into our ongoing projects. A big thank you to BerufsVerband Oecotrophologie e. V. (VDOE) for organizing such a well-executed conference. We can't wait for next year! #KONGRESSERNÄHRUNG2024 #SustainableHealth #CRS #Leipzig #IndustryInsights

📍 Live from Milan, Italy! Our Medical and Managing Director, Atef Dr Halabi is currently attending the EASL Congress 2024, hosted by EASL | The Home of Hepatology. This hybrid event stands as Europe's leading gathering for the hepatology community, uniting over 7,000 professionals worldwide to explore cutting-edge research and network with the top minds in the field. We're thrilled to be part of this inspiring event, shaping the future of hepatology. And the best part? It goes until tomorrow, so don't miss out — let's connect and make meaningful contributions together! 🤝 #EASL2024 #Hepatology #CRS #IndustryInsights #Milan

🌟💊Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 We are proud to announce that our very own clinical research investigator, Friedeborg Seitz, was a key contributor to a recent study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 in healthy volunteers. The study, conducted through rigorous Single Rising Dose (SRD) and Multiple Rising Dose (MRD) trials, provided valuable insights into the effects and potential of BI 685509. Highlights include: SRD Trial: 24 participants received single doses of BI 685509 or placebo, with key findings showing rapid absorption and dose-proportional exposure. MRD Trial: 60 participants received varying doses over 14–17 days, with observations of decreased orthostatic dysregulation over time and near-dose-proportional increases in exposure. The study confirmed BI 685509 was generally well tolerated, with manageable side effects. Join us in celebrating this achievement and the ongoing dedication of our team to excellence in clinical research! 👨🔬🔬 Read the full study here: https://lnkd.in/eC-6PwEd #CRS #Innovation #ClinicalResearch #PursuitofExcellence #Mannheim